Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "infection"

568 News Found

QIAGEN receives U.S. FDA emergency use authorization to analyze over 30 samples per hour
Digitisation | August 10, 2021

QIAGEN receives U.S. FDA emergency use authorization to analyze over 30 samples per hour

QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes


Apollo Hospitals successfully implants MitraClip
Healthcare | August 05, 2021

Apollo Hospitals successfully implants MitraClip

MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery


Govt committed to recognise healthcare workers engaged in Covid-19
Policy | August 04, 2021

Govt committed to recognise healthcare workers engaged in Covid-19

Five seats reserved for Wards of COVID warriors in central MBBS admission


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate
Biotech | August 02, 2021

Takeda and Frazier Healthcare Partners collaborates for Norovirus vaccine candidate

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines


Bharat Biotech gets WHO prequalification for ROTAVAC 5D
Biotech | August 02, 2021

Bharat Biotech gets WHO prequalification for ROTAVAC 5D

WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO


Biocon Biologics partners Adagio to manufacture antibody for COVID-19
News | July 27, 2021

Biocon Biologics partners Adagio to manufacture antibody for COVID-19

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses


Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
News | July 23, 2021

Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr

Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).


Zydus Cadila receives USFDA approval for Emtricitabine and Tenofovir Disoproxil
News | July 04, 2021

Zydus Cadila receives USFDA approval for Emtricitabine and Tenofovir Disoproxil

The drug is used with other HIV medications to help control HIV infection and it helps to decrease the amount of HIV in one’s body so that the immune system can work better